ArticleFrontiers in oncology2025
Preoperative plasma fibrinogen combined with the platelet-to-lymphocyte ratio (F-PLR) serves as a prognostic indicator in patients with non-small cell lung cancer.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The aim of this study was to explore the prognostic significance of the combined plasma fibrinogen level and platelet-to-lymphocyte ratio (F-PLR) score in patients who had undergone radical surgery for non-small cell lung cancer (NSCLC). Methods: In this study, we retrospectively reviewed the medical records of 214 patients who underwent radical resection for lung cancer. The optimal cut-off values for fibrinogen and the platelet - lymphocyte ratio (PLR) were determined by applying the receiver operating characteristic (ROC) curve and the Youden index. Based on these cut-off values, the patients were categorized into three groups: patients with elevated fibrinogen and PLR were assigned a score of 2; those with either elevated fibrinogen or PLR were assigned a score of 1; and those with neither elevation were assigned a score of 0. The Kaplan-Meier method was utilized to plot the survival curves, and differences among the curves were compared using the log - rank test. Univariate and multivariate analyses were carried out using the Cox proportional hazards model. Results: In this study, the optimal cutoff values were 3.90 for fibrinogen and 213.2 for the PLR. Cox's multifactorial analysis revealed that the implementation of adjuvant therapy after surgery(P<0.001), pathological stage(PStage=IIIA/I=0.041), and F-PLR(PF-PLR=1/0 = 0.006、PF-PLR=2/0 = 0.004)were independent prognostic factors influencing patient survival. Additionally, F-PLR was significantly correlated with the overall survival of NSCLC patients after surgery. Conclusions: The F-PLR score exhibits a significant association with the prognosis of NSCLC patients and can serve as a biomarker for predicting the prognosis of patients following NSCLC surgery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.